Company

About

Coare Biotechnology

Coare Biotechnology

Oklahoma City, Oklahoma, United States

COARE Biotechnology is a multidisciplinary drug development company that seeks to advance the current treatment modality of patients with aggressive cancers by coordinately targeting aspects of both the primary tumor and the biological processes that effect metastatic initiation and progression. Our team has garnered worldwide acclaim for their groundbreaking scientific discoveries in support of the novel therapeutic platforms developed here at COARE Biotechnology. We have identified key components within cancer biology that have not been targeted – until now.

Moleculera Biosciences

Moleculera Biosciences

755 Research Pkwy, Suite 410, Oklahoma City, Oklahoma 73104, US

Moleculera Biosciences offers advanced testing services in a fully-accredited CLIA/COLA clinical laboratory specializing in autoimmune neurobiology. As pioneers focusing on neuropsychiatric disorders caused by molecular mimicry, we offer the Autoimmune Brain Panel™, an aid to a physician's diagnosis of autoimmune-based neuropsychiatric disorders. The Autoimmune Brain Panel™ helps identify whether an individual's neurologic/psychiatric symptoms, such as obsessive compulsive behaviors, tics, anxiety, attention deficit hyperactivity disorder, and sometimes behaviors associated with Autism Spectrum Disorders, could be caused by a treatable autoimmune condition triggered by common infections.

Tetherex Pharmaceuticals

Tetherex Pharmaceuticals

Oklahoma City, OK

Tetherex Pharmaceuticals, a clinical-stage drug development company, was formed in 2014 as a spin-off of Selexys Pharmaceuticals to develop novel first-in-class therapeutics targeting cell adhesion proteins in inflammatory and oncologic diseases. Based on pioneering scientific work on the molecular mechanisms of cell adhesion and inflammation by our founding scientists, Tetherex is advancing new breakthrough therapeutics. Our lead selectin inhibitor clinical program is focused on a functionally blocking anti-PSGL-1 antibody called SelK2 which is currently under development for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Tetherex has also acquired an exclusive worldwide license from Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform which is currently under investigation as a vaccine for COVID-19. We invite you to explore our website and learn more about our highly experienced management team and our clinical development programs